行 业 及 产 业 医药生物 行 业 研 究 / 行 业 点 评 证 券 研 究 报 告 《本周申万医药生物指数下跌 0.8%，关注 基药目录发布——医药行业周报 （2026/02/09-2026/02/20）》 2026/02/23 《本周申万医药生物指数上涨 0.14%，关 注中药高质量发展方案——医药行业周报 （2026/02/02-2026/02/06）》 2026/02/09 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 陈田甜 A0230524080013 chentt@swsresearch.com 联系人 陈田甜 A0230524080013 chentt@swsresearch.com 2026 年 03 月 02 日 本 周 申 万 医 药 生 物 指 数 上 涨 0.5%，关注大宗原料药价格上涨 看好 —— 医药行业周报（2026/02/23-2026/02/27） 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 相关研究 ⚫ 市场表现：本周申万医药生物指数上涨 0.5%，同期 ...

我们不是资讯的搬运工 而是有态度的发现者 万和财富早班车 2026年2月27日 | 品种 | 收盘 | 涨跌幅 | 品种 | 收盘 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 上证指数 | 4146.63 | -0.01 % | 上证当月连续 | 3034.6 | -0.77% | | 深证成指 | 14503.79 | 0.19% | 沪深当月连续 | 4712.2 | -0.40% | | 创业板指 | 3344.98 | -0.29% | 恒生期货指数 | 33903.42 | -1.42% | 一、宏观消息汇总 1。央行26日开展3205亿元7天期逆回购操作，因有4000亿元14 天期逆回购到期，实现净回笼795亿元 2。商务部回应近期将举行的第六轮中美经贸磋商， 中美双方通 过中美经贸磋商机制，在各层级持续保持沟通 3。《中华人民共和国和德意志联邦共和国联合新闻声明》发布, 双方同意继续开展中德气候变化与绿色转型对话 二、行业最新动态 1. 高端白酒动销超预期，行业底部企稳趋势明朗，相关个股: 贵州茅台(600519)、五粮液(000858)等 2 ...

Core Viewpoint - The company, Ganli Pharmaceutical, is experiencing significant profit growth due to the benefits of centralized procurement, with a projected net profit increase of 100.73% to 114.12% in the first half of 2025 compared to the previous year [1][4]. Financial Performance - Ganli Pharmaceutical forecasts a net profit of 600 million to 640 million yuan for the first half of 2025, an increase of 301 million to 341 million yuan year-on-year [1]. - The company's non-recurring net profit is expected to be between 460 million and 500 million yuan, representing a year-on-year increase of 262.47% to 293.99% [1]. Growth Drivers - The revenue growth is attributed to both domestic and international sales increases, with domestic sales benefiting from a renewal of centralized procurement contracts and enhanced market coverage [4]. - The key driver for the profit doubling is the third-generation insulin's performance, which has seen both volume and price increases [4][6]. Procurement Strategy - In the latest round of insulin procurement, Ganli Pharmaceutical maintained a reasonable bidding price while controlling costs, allowing for greater profit retention [4]. - The new procurement rules have clarified price ranges, allowing for some price increases, which helps avoid excessive price wars that could harm profitability [4]. Cost Control Measures - The company employs a comprehensive cost control strategy throughout its operations, from product development to sales, enhancing efficiency and reducing costs [5]. - Ganli Pharmaceutical has established a lean management system across its supply chain, improving the interconnectivity of various operational stages [5]. Market Position and Product Performance - Ganli Pharmaceutical's products, including various insulin formulations, have seen price increases averaging 31% in the latest procurement round, with specific products like glargine insulin seeing a price rise of 48% [5][6]. - The company has secured a total of 46.86 million units in the latest procurement, a 32.6% increase from the previous round, with third-generation insulin products accounting for 30% of the total [6]. International Expansion - Since 2005, Ganli Pharmaceutical has been expanding its international presence, establishing a commercial network in over 20 countries and regions [8]. - The company is actively pursuing partnerships with leading pharmaceutical firms in emerging markets while also working on product certifications in Europe and the U.S. to enhance its global market influence [8].